Table 3.

FAB subtypes and cytogenetics of each patient at baseline


Patient no.

FAB subtype

Disease status at start of imatinib

Cytogenetic alterations involving the PDGF-R gene locus

Risk classification*/cytogenetic analysis
1   M4   3rd relapse   Negative   Intermediate/46,XY  
2   M2   1st relapse   Negative   Intermediate/del(12)(p)  
3   ND   2nd relapse   Negative   Poor/t(11;19)(q23;p13)  
4   ND   Refractory   Negative   Poor/complex abnormalities; del(3)(q)  
5   M2   1st relapse   Negative   Intermediate/del(20(q)  
6   M2   1st relapse   Negative   Intermediate/45,X  
7   M1   Refractory   Negative   Intermediate/46,XY  
8   M5b   Refractory   Negative   Intermediate/trisomy 21  
9   M2   1st relapse   Negative   Poor/complex abnormalities; -7  
10   Sec AML   Refractory   Negative   Intermediate/46,XY  
11   ND   1st relapse   Negative   Intermediate/46,XX  
12   M4   Chemonaive   Negative   Intermediate/46,XX  
13   ND   1st relapse   Negative   Intermediate/46,XX  
14   M5a   Chemonaive   Negative   Intermediate/46,XX, del(20)(q)  
15   M5a   1st relapse   Negative   Poor/del(5)(q)  
16   ND   1st relapse   ND   ND  
17   M0   Refractory   Negative   Poor/-7; inv(3)(qq)  
18   M5a   1st relapse   Negative   Poor/complex abnormalities; -7  
19   M0   1st relapse   Negative   Poor/complex abnormalities; -7;-3  
20   ND   1st relapse   Negative   Poor/complex abnormalities; -5  
21
 
ND
 
Chemonaive
 
Negative
 
Intermediate/46,XY
 

Patient no.

FAB subtype

Disease status at start of imatinib

Cytogenetic alterations involving the PDGF-R gene locus

Risk classification*/cytogenetic analysis
1   M4   3rd relapse   Negative   Intermediate/46,XY  
2   M2   1st relapse   Negative   Intermediate/del(12)(p)  
3   ND   2nd relapse   Negative   Poor/t(11;19)(q23;p13)  
4   ND   Refractory   Negative   Poor/complex abnormalities; del(3)(q)  
5   M2   1st relapse   Negative   Intermediate/del(20(q)  
6   M2   1st relapse   Negative   Intermediate/45,X  
7   M1   Refractory   Negative   Intermediate/46,XY  
8   M5b   Refractory   Negative   Intermediate/trisomy 21  
9   M2   1st relapse   Negative   Poor/complex abnormalities; -7  
10   Sec AML   Refractory   Negative   Intermediate/46,XY  
11   ND   1st relapse   Negative   Intermediate/46,XX  
12   M4   Chemonaive   Negative   Intermediate/46,XX  
13   ND   1st relapse   Negative   Intermediate/46,XX  
14   M5a   Chemonaive   Negative   Intermediate/46,XX, del(20)(q)  
15   M5a   1st relapse   Negative   Poor/del(5)(q)  
16   ND   1st relapse   ND   ND  
17   M0   Refractory   Negative   Poor/-7; inv(3)(qq)  
18   M5a   1st relapse   Negative   Poor/complex abnormalities; -7  
19   M0   1st relapse   Negative   Poor/complex abnormalities; -7;-3  
20   ND   1st relapse   Negative   Poor/complex abnormalities; -5  
21
 
ND
 
Chemonaive
 
Negative
 
Intermediate/46,XY
 

PN indicates patient number; FAB, French-American-British classification group; ND, not determined; and refractory, failure of initial therapy.

*

According to risk group definition of the HOVON/SAKK (Dutch-Belgian Cooperative Hemato-Oncology/Swiss Cancer study) group.50 

Close Modal

or Create an Account

Close Modal
Close Modal